{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "A drug widely available in Europe that may reduce the urge to drink is being tested in the United States, which has an estimated 13.7 million alcoholics. Its French maker hopes to have it on the American market in 2000. Many experts on dependency say the drug -- acamprosate, which would be sold in the United States as Campral -- is badly needed. Only two other medications can treat alcoholism, and both can have unpleasant or potentially dangerous side effects.", "headline": {"main": "Curbing the Urge to Drink; Drug to Treat Alcoholism Sets Off Controversy in U.S."}, "abstract": "Acamprosate, drug widely available in Europe that may reduce urge to drink, is being tested in US, which has estimated 13.7 million alcoholics; Lipha SA, unit of German drug maker Merck KGaA, hopes to have it on American market in 2000; doctors say they can prescribe drug to help alcoholics remain sober, possibly saving thousands of people from painful relapses while reducing cost of rehabilitation, which was $5 billion in 1997; expected arrival of drug has ignited controversy in health care community, pitting specialists who argue that alcoholics should be treated with counseling alone against doctors who insist that drugs are crucial tools; chart; photo (M)", "print_page": "1", "word_count": 1473, "_id": "4fd1e0188eb7c8105d726882", "snippet": "A drug widely available in Europe that may reduce the urge to drink is being tested in the United States, which has an estimated 13.7 million alcoholics. Its French maker hopes to have it on the American market in 2000.    Many experts on dependency...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1998/07/31/business/curbing-the-urge-to-drink-drug-to-treat-alcoholism-sets-off-controversy-in-us.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "MERCK KGAA"}, {"name": "organizations", "value": "LIPHA SA"}, {"name": "subject", "value": "ALCOHOL ABUSE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ACAMPROSATE (DRUG)"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "THERAPY AND REHABILITATION"}], "byline": {"person": [{"firstname": "David", "middlename": "J.", "lastname": "MORROW", "rank": 1, "role": "reported", "organization": ""}], "original": "By DAVID J. MORROW"}, "document_type": "article", "pub_date": "1998-07-31T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 1, "offset": 0, "time": 29}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}